{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T10:25:33Z","timestamp":1785234333071,"version":"3.55.0"},"reference-count":79,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,7,7]],"date-time":"2023-07-07T00:00:00Z","timestamp":1688688000000},"content-version":"am","delay-in-days":371,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["La Revue de M\u00e9decine Interne"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1016\/j.revmed.2022.04.030","type":"journal-article","created":{"date-parts":[[2022,5,31]],"date-time":"2022-05-31T08:21:24Z","timestamp":1653985284000},"page":"406-411","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["L\u2019hydroxychloroquine pour la sarco\u00efdose extra-pulmonaire non-s\u00e9v\u00e8re"],"prefix":"10.1016","volume":"43","author":[{"given":"Y.","family":"Jamilloux","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"El Jammal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Bert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"S\u00e8ve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.revmed.2022.04.030_bib0400","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/S0140-6736(13)60680-7","article-title":"Sarcoidosis","volume":"383","author":"Valeyre","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.revmed.2022.04.030_bib0405","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1001\/jama.2011.10","article-title":"clinical presentation, immunopathogenesis, and therapeutics","volume":"305","author":"Iannuzzi","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.revmed.2022.04.030_bib0410","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/S0140-6736(03)12888-7","article-title":"Sarcoidosis","volume":"361","author":"Baughman","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.revmed.2022.04.030_bib0415","first-page":"4","article-title":"Sarcoidosis: patient treatment priorities","author":"Baughman","year":"2018","journal-title":"ERJ Open Res"},{"key":"10.1016\/j.revmed.2022.04.030_bib0420","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1183\/09031936.00226911","article-title":"Global burden of chronic pulmonary aspergillosis complicating sarcoidosis","volume":"41","author":"Denning","year":"2013","journal-title":"Eur Respir J"},{"key":"10.1016\/j.revmed.2022.04.030_bib0425","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/1750-1172-2-46","article-title":"Sarcoidosis","volume":"2","author":"Nunes","year":"2007","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.revmed.2022.04.030_bib0430","first-page":"29","article-title":"Sarcoidosis: epidemiology and prognosis. A 15-year European study","volume":"130","author":"Hillerdal","year":"1984","journal-title":"Am Rev Respir Dis"},{"key":"10.1016\/j.revmed.2022.04.030_bib0435","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1093\/oxfordjournals.aje.a009096","article-title":"Racial differences in sarcoidosis incidence: a 5-year study in a health maintenance organization","volume":"145","author":"Rybicki","year":"1997","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.revmed.2022.04.030_bib0440","doi-asserted-by":"crossref","first-page":"S24","DOI":"10.1016\/j.rmed.2017.11.008","article-title":"Everyday cognitive failure and depressive symptoms predict fatigue in sarcoidosis: A prospective follow-up study","volume":"138S","author":"Hendriks","year":"2018","journal-title":"Respir Med"},{"key":"10.1016\/j.revmed.2022.04.030_bib0445","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.ccm.2015.08.013","article-title":"Consequences of Sarcoidosis","volume":"36","author":"Drent","year":"2015","journal-title":"Clin Chest Med"},{"key":"10.1016\/j.revmed.2022.04.030_bib0450","first-page":"54","article-title":"Exome sequencing and pathogenicity-network analysis of 5\u00a0French families implicate mTOR signalling and autophagy in familial sarcoidosis","author":"Calender","year":"2019","journal-title":"Eur Respir J"},{"key":"10.1016\/j.revmed.2022.04.030_bib0455","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/ni.3655","article-title":"Chronic signaling via the metabolic checkpoint kinase mTORC1\u00a0induces macrophage granuloma formation and marks sarcoidosis progression","volume":"18","author":"Linke","year":"2017","journal-title":"Nat Immunol"},{"key":"10.1016\/j.revmed.2022.04.030_bib0460","doi-asserted-by":"crossref","first-page":"983","DOI":"10.3390\/jcm10050983","article-title":"Immunohistochemical detection of potential microbial antigens in granulomas in the diagnosis of sarcoidosis","volume":"10","author":"Yamaguchi","year":"2021","journal-title":"J Clin Med"},{"key":"10.1016\/j.revmed.2022.04.030_bib0465","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1136\/thoraxjnl-2019-214348","article-title":"BTS Clinical Statement on pulmonary sarcoidosis","volume":"76","author":"Thillai","year":"2021","journal-title":"Thorax"},{"key":"10.1016\/j.revmed.2022.04.030_bib0470","first-page":"149","article-title":"Statement on Sarcoidosis","volume":"16","author":"Hunninghake","year":"1999","journal-title":"Sarc Vasc Diff Lung Dis"},{"key":"10.1016\/j.revmed.2022.04.030_bib0475","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1016\/j.rmed.2012.01.013","article-title":"The treatment of pulmonary sarcoidosis","volume":"106","author":"Judson","year":"2012","journal-title":"Respir Med"},{"key":"10.1016\/j.revmed.2022.04.030_bib0480","first-page":"325","article-title":"Current and emerging pharmacological treatments for sarcoidosis: a review","volume":"7","author":"Beegle","year":"2013","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.revmed.2022.04.030_bib0485","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1055\/s-2007-970335","article-title":"Extrapulmonary sarcoidosis","volume":"28","author":"Judson","year":"2007","journal-title":"Semin Respir Crit Care Med"},{"key":"10.1016\/j.revmed.2022.04.030_bib0490","doi-asserted-by":"crossref","first-page":"190145","DOI":"10.1183\/16000617.0145-2019","article-title":"Clinical phenotyping: role in treatment decisions in sarcoidosis","volume":"29","author":"Baughman","year":"2020","journal-title":"Eur Respir Rev"},{"key":"10.1016\/j.revmed.2022.04.030_bib0495","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.04079-2020","article-title":"ERS clinical practice guidelines on treatment of sarcoidosis","author":"Baughman","year":"2021","journal-title":"Eur Respir J"},{"key":"10.1016\/j.revmed.2022.04.030_bib0500","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1097\/MCP.0000000000000604","article-title":"Indications for treatment of sarcoidosis","volume":"25","author":"Nunes","year":"2019","journal-title":"Curr Opin Pulm Med"},{"key":"10.1016\/j.revmed.2022.04.030_bib0505","first-page":"51","article-title":"Phenotypes of organ involvement in sarcoidosis","author":"Schupp","year":"2018","journal-title":"Eur Respir J"},{"key":"10.1016\/j.revmed.2022.04.030_bib0510","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1378\/chest.115.4.1158","article-title":"An approach to the treatment of pulmonary sarcoidosis with corticosteroids: the six phases of treatment","volume":"115","author":"Judson","year":"1999","journal-title":"Chest"},{"key":"10.1016\/j.revmed.2022.04.030_bib0515","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.rmed.2017.09.003","article-title":"Toxicity risk from glucocorticoids in sarcoidosis patients","volume":"132","author":"Khan","year":"2017","journal-title":"Respir Med"},{"key":"10.1016\/j.revmed.2022.04.030_bib0520","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S2213-2600(15)00199-X","article-title":"New treatment strategies for pulmonary sarcoidosis: antimetabolites, biological drugs, and other treatment approaches","volume":"3","author":"Baughman","year":"2015","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.revmed.2022.04.030_bib0525","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1007\/s00198-017-3962-y","article-title":"Risk of fragility fracture among patients with sarcoidosis: a population-based study 1976-2013","volume":"28","author":"Ungprasert","year":"2017","journal-title":"Osteoporos Int J"},{"key":"10.1016\/j.revmed.2022.04.030_bib0530","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.semarthrit.2017.03.005","article-title":"Efficacy and safety of tumor necrosis factor antagonists in refractory sarcoidosis: A multicenter study of 132\u00a0patients","volume":"47","author":"Jamilloux","year":"2017","journal-title":"Semin Arthritis Rheum"},{"issue":"11","key":"10.1016\/j.revmed.2022.04.030_bib0535","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1136\/bjophthalmol-2020-317354","article-title":"Recommendations for the management of ocular sarcoidosis from the International Workshop on Ocular Sarcoidosis","volume":"105","author":"Takase","year":"2021","journal-title":"Br J Ophthalmol"},{"issue":"4","key":"10.1016\/j.revmed.2022.04.030_bib0540","doi-asserted-by":"crossref","first-page":"e3","DOI":"10.2106\/JBJS.RVW.N.00082","article-title":"Osseous Sarcoidosis","volume":"3","author":"Gowani","year":"2015","journal-title":"JBJS Rev"},{"key":"10.1016\/j.revmed.2022.04.030_bib0545","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.semarthrit.2014.07.003","article-title":"Osseous sarcoidosis: clinical characteristics, treatment, and outcomes--experience from a large, academic hospital","volume":"44","author":"Sparks","year":"2014","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.revmed.2022.04.030_bib0550","doi-asserted-by":"crossref","first-page":"83","DOI":"10.2174\/1573397114666180425111901","article-title":"Musculoskeletal manifestations of sarcoidosis: a review article","volume":"15","author":"Shariatmaghani","year":"2019","journal-title":"Curr Rheumatol Rev"},{"key":"10.1016\/j.revmed.2022.04.030_bib0555","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1016\/j.rmed.2017.12.009","article-title":"Steroids for sarcoidosis: how much and for how long?","volume":"138","author":"Baughman","year":"2018","journal-title":"Respir Med"},{"key":"10.1016\/j.revmed.2022.04.030_bib0560","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1136\/thx.54.8.742","article-title":"A clinical approach to the use of methotrexate for sarcoidosis","volume":"54","author":"Baughman","year":"1999","journal-title":"Thorax"},{"key":"10.1016\/j.revmed.2022.04.030_bib0575","first-page":"26","article-title":"Management of ocular sarcoidosis","volume":"29","author":"Baughman","year":"2012","journal-title":"Sarc Vasc Diff Lung Dis"},{"key":"10.1016\/j.revmed.2022.04.030_bib0580","first-page":"S183","article-title":"Use of methotrexate in patients with sarcoidosis","volume":"28","author":"Kiltz","year":"2010","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.revmed.2022.04.030_bib0585","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/S0161-6420(99)90011-8","article-title":"Methotrexate treatment for sarcoid-associated panuveitis","volume":"106","author":"Dev","year":"1999","journal-title":"Ophthalmology"},{"key":"10.1016\/j.revmed.2022.04.030_bib0570","first-page":"60","article-title":"Methotrexate is steroid sparing in acute sarcoidosis: Results of a double blind, randomized trial","volume":"17","author":"Baughman","year":"2000","journal-title":"Sarc Vasc Diff Lung Dis"},{"key":"10.1016\/j.revmed.2022.04.030_bib0565","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1001\/archinte.1995.00430080088011","article-title":"Prolonged use of methotrexate for sarcoidosis","volume":"155","author":"Lower","year":"1995","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.revmed.2022.04.030_bib0590","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1378\/chest.12-1728","article-title":"Methotrexate vs azathioprine in second-line therapy of sarcoidosis","volume":"144","author":"Vorselaars","year":"2013","journal-title":"Chest"},{"key":"10.1016\/j.revmed.2022.04.030_bib0595","first-page":"43","article-title":"Leflunomide for chronic sarcoidosis","volume":"21","author":"Baughman","year":"2004","journal-title":"Sarc Vasc DiffLung Dis"},{"key":"10.1016\/j.revmed.2022.04.030_bib0600","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1183\/09031936.00195010","article-title":"Effectiveness and safety of leflunomide for pulmonary and extrapulmonary sarcoidosis","volume":"38","author":"Sahoo","year":"2011","journal-title":"Eur Respir J"},{"key":"10.1016\/j.revmed.2022.04.030_bib0605","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1212\/WNL.0b013e318212aafb","article-title":"Mycophenolate mofetil may be effective in CNS sarcoidosis but not in sarcoid myopathy","volume":"76","author":"Androdias","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.revmed.2022.04.030_bib0610","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1080\/09273940902862992","article-title":"Mycophenolate mofetil therapy for sarcoidosis-associated uveitis","volume":"17","author":"Bhat","year":"2009","journal-title":"Ocul Immunol Inflamm"},{"issue":"12","key":"10.1016\/j.revmed.2022.04.030_bib0615","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1016\/j.cardfail.2021.06.010","article-title":"Management of Cardiac Sarcoidosis Using Mycophenolate Mofetil as a Steroid Sparing Agent","volume":"27","author":"Griffin","year":"2021","journal-title":"J Card Fail"},{"key":"10.1016\/j.revmed.2022.04.030_bib0620","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1212\/WNL.0000000000003431","article-title":"Treatment of neurosarcoidosis: a comparative study of methotrexate and mycophenolate mofetil","volume":"87","author":"Bitoun","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.revmed.2022.04.030_bib0625","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1016\/j.rmed.2014.09.013","article-title":"Efficacy of mycophenolate mofetil in sarcoidosis","volume":"108","author":"Hamzeh","year":"2014","journal-title":"Respir Med"},{"key":"10.1016\/j.revmed.2022.04.030_bib0630","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1164\/rccm.200603-402OC","article-title":"Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement","volume":"174","author":"Baughman","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.revmed.2022.04.030_bib0635","first-page":"46","article-title":"Efficacy Results of a 52-week trial of adalimumab in the treatment of refractory sarcoidosis","volume":"31","author":"Sweiss","year":"2014","journal-title":"Sarc Vasc Diff Lung Dis"},{"key":"10.1016\/j.revmed.2022.04.030_bib0640","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1183\/09031936.00000914","article-title":"Safety and efficacy of ustekinumab or golimumab in patients with chronic sarcoidosis","volume":"44","author":"Judson","year":"2014","journal-title":"Eur Respir J"},{"key":"10.1016\/j.revmed.2022.04.030_bib0645","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1007\/s00417-011-1844-0","article-title":"Adalimumab successful in sarcoidosis patients with refractory chronic non-infectious uveitis","volume":"250","author":"Erckens","year":"2012","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.revmed.2022.04.030_bib0650","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1183\/09031936.00051907","article-title":"Efficacy of infliximab in extrapulmonary sarcoidosis: results from a randomised trial","volume":"31","author":"Judson","year":"2008","journal-title":"Eur Respir J"},{"key":"10.1016\/j.revmed.2022.04.030_bib0655","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1183\/09031936.00049808","article-title":"Infliximab in extrapulmonary sarcoidosis: tantalising but inconclusive","volume":"31","author":"Wells","year":"2008","journal-title":"Eur Respir J"},{"key":"10.1016\/j.revmed.2022.04.030_bib0660","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/j.jaad.2012.10.056","article-title":"A double-blind, randomized, placebo-controlled trial of adalimumab in the treatment of cutaneous sarcoidosis","volume":"68","author":"Pariser","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.revmed.2022.04.030_bib0665","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1111\/j.1529-8019.2007.00131.x","article-title":"New concepts in antimalarial use and mode of action in dermatology","volume":"20","author":"Kalia","year":"2007","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.revmed.2022.04.030_bib0670","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1073\/pnas.79.1.175","article-title":"Decrease in macrophage antigen catabolism caused by ammonia and chloroquine is associated with inhibition of antigen presentation to T cells","volume":"79","author":"Ziegler","year":"1982","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.revmed.2022.04.030_bib0675","article-title":"Phagosome-regulated mTOR Signalling during Sarcoidosis Granuloma Biogenesis","author":"Crouser","year":"2020","journal-title":"Eur Respir J"},{"key":"10.1016\/j.revmed.2022.04.030_bib0680","first-page":"55","article-title":"Chloroquine and hydroxychloroquine equally affect tumor necrosis factor-alpha, interleukin 6, and interferon-gamma production by peripheral blood mononuclear cells","volume":"24","author":"van den Borne","year":"1997","journal-title":"J Rheumatol"},{"key":"10.1016\/j.revmed.2022.04.030_bib0685","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1191\/0961203306lu2299oa","article-title":"Chloroquine treatment influences proinflammatory cytokine levels in systemic lupus erythematosus patients","volume":"15","author":"Wozniacka","year":"2006","journal-title":"Lupus"},{"key":"10.1016\/j.revmed.2022.04.030_bib0690","doi-asserted-by":"crossref","first-page":"3068","DOI":"10.1002\/art.22157","article-title":"Antimalarial agents: closing the gate on Toll-like receptors?","volume":"54","author":"Lafyatis","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.revmed.2022.04.030_bib0695","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/0005-2760(85)90114-6","article-title":"Effects of antimalarial drugs on phospholipase A and lysophospholipase activities in plasma membrane, mitochondrial, microsomal and cytosolic subcellular fractions of rat liver","volume":"835","author":"L\u00f6ffler","year":"1985","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.revmed.2022.04.030_bib0700","doi-asserted-by":"crossref","DOI":"10.1111\/j.0954-6820.1964.tb05780.x","article-title":"Chloroquine therapy in 43\u00a0patients with intrathoracic and cutaneous sarcoidosis","author":"Siltzbach","year":"1964","journal-title":"Acta Med Scand"},{"key":"10.1016\/j.revmed.2022.04.030_bib0705","first-page":"257","article-title":"Chloroquine in the treatment of sarcoidosis. A report from the Research Committee of the British Tuberculosis Association","volume":"48","year":"1967","journal-title":"Tubercle"},{"key":"10.1016\/j.revmed.2022.04.030_bib0710","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1164\/ajrccm.160.1.9809024","article-title":"Randomized trial of prolonged chloroquine therapy in advanced pulmonary sarcoidosis","volume":"160","author":"Baltzan","year":"1999","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.revmed.2022.04.030_bib0715","first-page":"3736","article-title":"Experience of hydroxychloroquine in the treatment of pulmonary sarcoidosis in the west of Ireland: An insight into clinical practice","volume":"38","author":"McDonnell","year":"2011","journal-title":"Eur Respir J"},{"key":"10.1016\/j.revmed.2022.04.030_bib0720","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1001\/archneur.55.9.1248","article-title":"Effectiveness of chloroquine and hydroxychloroquine in treating selected patients with sarcoidosis with neurological involvement","volume":"55","author":"Sharma","year":"1998","journal-title":"Arch Neurol"},{"key":"10.1016\/j.revmed.2022.04.030_bib0725","first-page":"1066","article-title":"Evolution favorable d\u2019une forme pseudo-tumorale de sarco\u00efdose h\u00e9patique et spl\u00e9nique sous traitement par hydroxychloroquine et colchicine","volume":"19","author":"Joundy","year":"1995","journal-title":"Gastroenterol Clin Biol"},{"key":"10.1016\/j.revmed.2022.04.030_bib0730","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/S0002-9343(89)80409-7","article-title":"Granulomatous infiltration of the talus and abnormal vitamin D and calcium metabolism in a patient with sarcoidosis: successful treatment with hydroxychloroquine","volume":"87","author":"DeSimone","year":"1989","journal-title":"Am J Med"},{"key":"10.1016\/j.revmed.2022.04.030_bib0735","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/0190-9622(90)70246-E","article-title":"Hydroxychloroquine is effective therapy for control of cutaneous sarcoidal granulomas","volume":"23","author":"Jones","year":"1990","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.revmed.2022.04.030_bib0740","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1016\/0002-9343(87)90237-3","article-title":"Hydroxychloroquine treatment of hypercalcemia in a patient with sarcoidosis undergoing hemodialysis","volume":"82","author":"Barre","year":"1987","journal-title":"Am J Med"},{"key":"10.1016\/j.revmed.2022.04.030_bib0745","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1111\/j.1365-4362.1996.tb03710.x","article-title":"Intralesional chloroquine for the treatment of cutaneous sarcoidosis","volume":"35","author":"Liedtka","year":"1996","journal-title":"Int J Dermatol"},{"issue":"4","key":"10.1016\/j.revmed.2022.04.030_bib0750","first-page":"351","article-title":"Micropapular cutaneous sarcoidosis: case series successfully managed with hydroxychloroquine sulfate","volume":"81","author":"Modi","year":"2008","journal-title":"Cutis"},{"key":"10.1016\/j.revmed.2022.04.030_bib0755","doi-asserted-by":"crossref","first-page":"13","DOI":"10.3109\/01676830.2010.524268","article-title":"Orbital sarcoidosis treated with hydroxychloroquine","volume":"30","author":"Rabinowitz","year":"2011","journal-title":"Orbit"},{"issue":"6","key":"10.1016\/j.revmed.2022.04.030_bib0760","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.jbspin.2019.07.009","article-title":"Osseous sarcoidosis: A multicenter retrospective case-control study of 48\u00a0patients","volume":"86","author":"Ben Hassine","year":"2019","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.revmed.2022.04.030_bib0765","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1136\/pgmj.74.869.172","article-title":"Sarcoidosis of the paranasal sinuses treated with hydroxychloroquine","volume":"74","author":"Hassid","year":"1998","journal-title":"Postgrad Med J"},{"key":"10.1016\/j.revmed.2022.04.030_bib0770","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1056\/NEJM198609183151203","article-title":"The effects of chloroquine on serum 1,25-dihydroxyvitamin D and calcium metabolism in sarcoidosis","volume":"315","author":"O\u2019Leary","year":"1986","journal-title":"N Engl J Med"},{"key":"10.1016\/j.revmed.2022.04.030_bib0775","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/0002-9343(61)90213-3","article-title":"The treatment of sarcoidosis with chloroquine","volume":"30","author":"Morse","year":"1961","journal-title":"Am J Med"},{"key":"10.1016\/j.revmed.2022.04.030_bib0780","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1001\/jamaneurol.2017.2492","article-title":"Association of prognostic factors and immunosuppressive treatment with long-term outcomes in Neurosarcoidosis","volume":"74","author":"Joubert","year":"2017","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.revmed.2022.04.030_bib0785","doi-asserted-by":"crossref","first-page":"A72","DOI":"10.1016\/j.revmed.2021.03.286","article-title":"L\u2019Hydroxychloroquine: un traitement d\u2019\u00e9pargne cortisonique dans l\u2019uv\u00e9ite sarco\u00efdosique","volume":"42","author":"Bert","year":"2021","journal-title":"Rev Med Interne"},{"key":"10.1016\/j.revmed.2022.04.030_bib0395","doi-asserted-by":"crossref","first-page":"565420","DOI":"10.3389\/fmed.2020.565420","article-title":"Acute and Chronic sarcoid arthropathies: characteristics and treatments from a retrospective nationwide French Study","volume":"7","author":"Cacciatore","year":"2020","journal-title":"Front Med"}],"container-title":["La Revue de M\u00e9decine Interne"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0248866322004532?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0248866322004532?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T16:45:29Z","timestamp":1759337129000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0248866322004532"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":79,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["S0248866322004532"],"URL":"https:\/\/doi.org\/10.1016\/j.revmed.2022.04.030","relation":{},"ISSN":["0248-8663"],"issn-type":[{"value":"0248-8663","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"L\u2019hydroxychloroquine pour la sarco\u00efdose extra-pulmonaire non-s\u00e9v\u00e8re","name":"articletitle","label":"Article Title"},{"value":"La Revue de M\u00e9decine Interne","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.revmed.2022.04.030","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Soci\u00e9t\u00e9 Nationale Fran\u00e7aise de M\u00e9decine Interne (SNFMI). Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}